Tianjin Zhong Xin Pharmaceutical's earnings drop 12% to 352.3m yuan
Singapore
TRADITIONAL Chinese medicine group Tianjin Zhong Xin Pharmaceutical Group Corporation Ltd registered a 12 per cent year-on-year fall in net profit, from 399.9 million yuan (S$69.1 million) to 352.3 million yuan for the financial year ended Dec 31, 2013.
The decrease came mainly from the disposal of a subsidiary, Tianjin Central, and a decrease in share of profits from an associated company, Tianjin Smithkline & French Lab Ltd, compared to the corresponding period in FY2012. Excluding the impact of Tianjin Central and Tianjin Cinorch, operating profit of the group (excluding investment income) increased by 88 million yuan, or 41 per cent compared to the corresponding period in FY2012.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Spotify sued over alleged unpaid royalties
Keppel Reit unit obtains 131 billion won loan facility
US: Wall St inches up, set for weekly gains on rate-cut hopes
India's Zee Entertainment reports Q4 profit as advertising demand picks up
Halcyon Agri posts 88.2% rise in Q1 Ebitda
Keppel’s data centres CEO to become senior managing director, M1 CEO to helm connectivity portfolio